Evidence map›Paper›PMID 32908946›Full record

ArticleArXiv2023

Semi-parametric modeling of SARS-CoV-2 transmission using tests, cases, deaths, and seroprevalence data.

Damon Bayer, Isaac H Goldstein, Jonathan Fintzi, Keith Lumbard, Emily Ricotta, Sarah Warner, Lindsay M Busch, Jeffrey R Strich, Daniel S Chertow, Daniel M Parker and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in ArXiv, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 2 countries.

Damon BayerDepartment of Statistics, University of California, Irvine, California, U.S.A.
Isaac H GoldsteinDepartment of Statistics, University of California, Irvine, California, U.S.A.
Jonathan FintziBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, U.S.A.
Keith LumbardClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, U.S.A.
Emily RicottaEpidemiology Unit, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, U.S.A.
Sarah WarnerCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, U.S.A.
Lindsay M BuschDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, U.S.A.
Jeffrey R StrichCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, U.S.A.
Daniel S ChertowCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, U.S.A.
Daniel M ParkerSusan and Henry Samueli College of Health Sciences, University of California, Irvine, California, U.S.A.
Bernadette Boden-AlbalaSusan and Henry Samueli College of Health Sciences, University of California, Irvine, California, U.S.A.
Alissa DratchOrange County Health Care Agency, Santa Ana, California, U.S.A.
Richard ChhuonOrange County Health Care Agency, Santa Ana, California, U.S.A.
Nichole QuickKCS Health Center, Buena Park, California, U.S.A.
Matthew ZahnOrange County Health Care Agency, Santa Ana, California, U.S.A.
Volodymyr M MininDepartment of Statistics, University of California, Irvine, California, U.S.A.
University of California, Irvine · USNational Institutes of Health Clinical Center · USNational Institute of Allergy and Infectious Diseases · USOrange County Healthcare Agency · USEdwards Lifesciences (Switzerland) · CHEmory University · USFrederick National Laboratory for Cancer Research · USLos Angeles County Department of Public Health · USSamueli Institute · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Improved understanding of TB transmission by accounting for within-host heterogeneity of M. tuberculosis: A population-based molecular epidemiology study in a high HIV prevalent settingR01AI147336 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI SHIN, SANGHYUK SAM · 2020 to 2024
$3.3M
The effect of HIV on SARS-CoV-2 transmission and emergence of variants of concernR01AI170204 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI MODONGO, CHAWANGWA, NIEMANN, STEFAN · 2022 to 2025
$2.4M
NCI NIH HHS 75N91019D00024NIAID NIH HHS R01 AI147336NIAID NIH HHS R01 AI170204
6 · The paper itself

Abstract

Mechanistic models fit to streaming surveillance data are critical to understanding the transmission dynamics of an outbreak as it unfolds in real-time. However, transmission model parameter estimation can be imprecise, and sometimes even impossible, because surveillance data are noisy and not informative about all aspects of the mechanistic model. To partially overcome this obstacle, Bayesian models have been proposed to integrate multiple surveillance data streams. We devised a modeling framework for integrating SARS-CoV-2 diagnostics test and mortality time series data, as well as seroprevalence data from cross-sectional studies, and tested the importance of individual data streams for both inference and forecasting. Importantly, our model for incidence data accounts for changes in the total number of tests performed. We model the transmission rate, infection-to-fatality ratio, and a parameter controlling a functional relationship between the true case incidence and the fraction of positive tests as time-varying quantities and estimate changes of these parameters nonparametrically. We compare our base model against modified versions which do not use diagnostics test counts or seroprevalence data to demonstrate the utility of including these often unused data streams. We apply our Bayesian data integration method to COVID-19 surveillance data collected in Orange County, California between March 2020 and February 2021 and find that 32-72% of the Orange County residents experienced SARS-CoV-2 infection by mid-January, 2021. Despite this high number of infections, our results suggest that the abrupt end of the winter surge in January 2021 was due to both behavioral changes and a high level of accumulated natural immunity.

Identifiers

PMID32908946
PMCPMC7480029
OpenAlexW3083168836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.